Eisai Co. of Japan will expand its China operations by acquiring generic drugmaker Liaoning TianYi Biological Pharma for $78 million. TianYi has China approval for 90 products, including both chemical drugs and TCM products. It currently markets about 20 of these and also produces APIs. With the acquisition, Eisai enters the hyper-competitive generic drug business in China for the first time; its current product line consists entirely of patent-protected drugs.
